866-997-4948(US-Canada Toll Free)

Waldenstrom Macroglobulinemia Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 149 Pages


Waldenstrom Macroglobulinemia Pipeline Review, H2 2012

Global Markets Directs, 'Waldenstrom Macroglobulinemia Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia. Waldenstrom Macroglobulinemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Waldenstrom Macroglobulinemia.
  • A review of the Waldenstrom Macroglobulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Waldenstrom Macroglobulinemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Waldenstrom Macroglobulinemia Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Waldenstrom Macroglobulinemia 12
Waldenstrom Macroglobulinemia Therapeutics under Development by Companies 14
Waldenstrom Macroglobulinemia Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Pre-Clinical Stage Products 22
Comparative Analysis 22
Waldenstrom Macroglobulinemia Therapeutics Products under Development by Companies 23
Waldenstrom Macroglobulinemia Therapeutics Products under Investigation by Universities/Institutes 24
Companies Involved in Waldenstrom Macroglobulinemia Therapeutics Development 27
Eli Lilly and Company 27
Millennium Pharmaceuticals, Inc. 28
Genmab A/S 29
Onyx Pharmaceuticals, Inc. 30
AEterna Zentaris Inc. 31
Accentia Biopharmaceuticals, Inc. 32
Allos Therapeutics, Inc 33
Avila Therapeutics, Inc. 34
Immune System Therapeutics Ltd. 35
Intellikine, Inc. 36
Waldenstrom Macroglobulinemia Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
perifosine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ixazomib citrate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
enzastaurin hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BiovaxID - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
MDX-1097 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
carfilzomib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
oprozomib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
INK-128 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
alemtuzumab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
sildenafil citrate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
LBH589 + RAD001 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
fludarabine phosphate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Yttrium Y 90 Epratuzumab + Peripheral Blood Stem Cell Transplantation + G-CSF - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Bortezomib + Dexamethasone + Rituximab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Beta Alethine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Folotyn + Gemcitabine Hydrochloride - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Pomalidomide + Dexamethasone + Rituximab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
panobinostat - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Rituximab + Bortezomib + Carmustine + Cisplatin + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin Hydrochloride + Etoposide + Melphalan + Thalidomide + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 70
Product Description 70
Mechanism of Action 71
R&D Progress 72
Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Campath + Fludarabine + Cyclosporine + Mycophenolate Mofetil + Peripheral Stem Cell Transplantation - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 77
bortezomib - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
dolastatin 10 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
perifosine - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
simvastatin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Interleukin-2 + GM-CSF - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ofatumumab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
RAD001 + Revlimid - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
bortezomib - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 90
Velcade + Rituxan + Valacyclovir - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
RAD001 + Velcade + Rituxan - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Velcade + Rituximab - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
rituximab - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 96
Ofatumumab + Bortezomib - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Lenalidomide + Rituximab + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplant - Drug Profile 98
Product Description 98
Mechanism of Action 99
R&D Progress 99
Filgrastim + Recombinant Interferon Alfa + Dexamethasone + Melphalan - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 102
Filgrastim + Recombinant Interferon Alfa + Dexamethasone + Melphalan - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 104
Rituximab + Bortezomib + Carmustine + Cisplatin + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin Hydrochloride + Etoposide + Melphalan + Thalidomide + Filgastrim + Stem Cell Transplantation - Drug Profile 105
Product Description 105
Mechanism of Action 106
R&D Progress 107
AVL-292 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
DT PACE + Rituxan - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
CC-5103 + Rituximab - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile 112
Product Description 112
Mechanism of Action 113
R&D Progress 114
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Cyclosporine + Mycophenolate Mofetil + Melphalan + Therapeutic Autologous Lymphocytes + Stem Cell Transplantation + Radiation Therapy - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 116
Fludarabine Phosphate + Total-Body Irradiation + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 119
Temsirolimus + Rituximab + Bortezomib + Dexamethasone - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
panobinostat - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Waldenstrom Macroglobulinemia Therapeutics Drug Profile Updates 126
Waldenstrom Macroglobulinemia Therapeutics Discontinued Products 142
Waldenstrom Macroglobulinemia Therapeutics - Dormant Products 143
Waldenstrom Macroglobulinemia Product Development Milestones 144
Featured News & Press Releases 144
Nov 08, 2011: Genmab To Present Data On Ofatumumab At 53rd American Society Of Hematology Annual Meeting And Exposition 144
Nov 07, 2011: Pharmacyclics Reports Multiple PCI-32765 Presentations At 53rd American Society Of Hematology Annual Meeting 145
Jun 29, 2007: Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on Krx-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia 146

Appendix 148
Methodology 148
Coverage 148
Secondary Research 148
Primary Research 148
Expert Panel Validation 148
Contact Us 149
Disclaimer 149

List of Table


Number of Products Under Development for Waldenstrom Macroglobulinemia, H2 2012 12
Products under Development for Waldenstrom Macroglobulinemia Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 18
Comparative Analysis by Late Stage Development, H2 2012 19
Comparative Analysis by Mid Clinical Stage Development, H2 2012 20
Comparative Analysis by Early Clinical Stage Development, H2 2012 21
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 25
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 26
Eli Lilly and Company, H2 2012 27
Millennium Pharmaceuticals, Inc., H2 2012 28
Genmab A/S, H2 2012 29
Onyx Pharmaceuticals, Inc., H2 2012 30
AEterna Zentaris Inc., H2 2012 31
Accentia Biopharmaceuticals, Inc., H2 2012 32
Allos Therapeutics, Inc, H2 2012 33
Avila Therapeutics, Inc., H2 2012 34
Immune System Therapeutics Ltd., H2 2012 35
Intellikine, Inc., H2 2012 36
Assessment by Monotherapy Products, H2 2012 37
Assessment by Combination Products, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 43
Waldenstrom Macroglobulinemia Therapeutics Drug Profile Updates 126
Waldenstrom Macroglobulinemia Therapeutics Discontinued Products 142
Waldenstrom Macroglobulinemia Therapeutics Dormant Products 143

List of Chart


Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2012 12
Products under Development for Waldenstrom Macroglobulinemia Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 19
Mid Clinical Stage Products, H2 2012 20
Early Clinical Stage Products, H2 2012 21
Pre-Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 37
Assessment by Combination Products, H2 2012 38
Assessment by Route of Administration, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Molecule Type, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *